Specifying a GLP 28-Day Repeat-Dose Toxicology, Toxicokinetic, and Immunogenicity Study of a Once-Weekly Basal Insulin Analogue in Rat and Dog: A Request-for-Proposal Framework Supporting FDA IND Submission
Insulin analogues designed for once-weekly administration change the safety-study problem in three ways: pharmacologic hypoglycemia limits the dose, species clear the molecule far faster than people do, and an antibody response can both alter exposure and cross-react with endogenous insulin. This article builds a request for proposal (RFP) for a GLP 28-day repeat-dose subcutaneous toxicology, toxicokinetic, and immunogenicity study in rat and dog with a 14-day recovery phase, for a hypothetical acylated basal insulin analogue that binds albumin reversibly. It sets out the class-level rationale, the applicable ICH, FDA, and EMA guidance, a modular scope, group and animal tables (150 animals), a glucose monitoring and hypoglycemia rescue plan, an eight-month schedule, a line-item budget with a total estimate of USD 751,351, and scoring criteria weighted toward GLP quality, insulin or peptide experience, and antibody capability. Recommendations close with advice on confidentiality and intellectual property in vendor relationships.Keywords: request for proposal; basal insulin analogue; repeat-dose toxicity; toxicokinetics; immunogenicity; hypoglycemia; ICH S6(R1); GLP
Authors
- Peivand Pirouzi
- Happy Makvana
- Drashti Patel
- Sahil Patel
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24425278
- Primary Topic
- Animal testing and alternatives
- Type
- article
- Field-Weighted Citation Impact
- 0.00